RGO:ETR
Regeneron Pharmaceuticals Inc
€685.10
arrow_upward
+0.53%(+3.60) 1D
Sep 18, 5:35:33 PM GMT+2 · EUR
search
All symbols
1D
5D
1M
6M
YTD
1Y
5Y
MAX
| Symbol | Price | Change | % Change |
|---|
insights_autoGenerating top insights for RGO...
Open
€685.90
High
€685.90
Low
€684.80
Mkt. cap
80.80B
Avg. vol.
54.00
Volume
0.00
52-wk high
€732.90
52-wk low
€464.70
No. of employees
15K
Open
€685.90
High
€685.90
Low
€684.80
Mkt. cap
80.80B
Avg. vol.
54.00
Volume
0.00
52-wk high
€732.90
52-wk low
€464.70
No. of employees
15K
News stories
From web sources and news partners
TipRanks
·
18 hours ago
Regeneron Stock Slumps After Tepid COPD Trial Update
TipRanks
·
1 day ago
Itepekimab COPD Extension Trial Completion: What It Means for Regeneron and Sanofi
AD HOC NEWS
·
1 day ago
Regeneron stock gains as lawsuits highlight pipeline risks and analyst targets stay supportive
CarePlus VietNam
·
1 month ago
REGN Q2 2026 Earnings: EPS Smashes Estimates by 36.5% - Final Results
Profile
Regeneron Pharmaceuticals, Inc. is an American biotechnology company headquartered in Westchester County, New York. The company was founded in 1988. Originally focused on neurotrophic factors and their regenerative capabilities, giving rise to its present name; the company has since expanded operations into the study of both cytokine and tyrosine kinase receptors, which gave rise to their first product, which is a VEGF-trap. Wikipedia
About Regeneron Pharmaceuticals Inc
CEOLeonard Schleifer
Employees15.3K
Founded1988
HeadquartersTarrytown, New York, United States
SectorBiotechnology
Websiteregeneron.com